Intranasal insulin reverts central pathology and cognitive impairment in diabetic mother offspring

Table 1 Metabolic assessment of STZ-treated mothers

	Treatment
	Control	STZ
Initial body weight (g)	30.72 ± 1.06	31.11 ± 1.45
Body weight (g) at birth	42.31 ± 1.31	35.76 ± 1.09**
Increase in body weight (g)	11.6 ± 1.45	5.43 ± 0.85**
Initial insulin levels (ng/ml)	0.63 ± 0.17	0.94 ± 0.24
Insulin levels (ng/dl) at birth	0.44 ± 0.14	0.03 ± 0.01
Initial glucose levels (mg/dl)	111.20 ± 5.08	112.75 ± 3.46
Glucose levels (mg/dl) before crossing	100.60 ± 10.54	184.38 ± 17.67**
Glucose levels (mg/dl) after crossing	111.40 ± 8.90	487.27 ± 44.27**
Glucose levels (mg/dl) at birth	94.00 ± 3.05	500.38 ± 39.29**

Initial body weight (p = 0.850), glucose levels (p = 0.798) or insulin levels (p = 0.382) were similar in both groups before STZ administration. Glucose levels immediately before crossing (one week after commencement of the treatment) were increased in STZ treated mice (**p = 0.005 vs. Control). The date of birth, body weight (**p = 0.003 vs. Control) and the increase of body weight (**p = 0.003 vs. Control) were significantly lower in STZ-treated mothers. The day of birth insulin levels were lower in STZ-treated animals (**p = 0.005 vs. Control) while glucose levels were increased after crossing and at birth (**p < 0.001 vs. Control)

ISSN: 1750-1326